4,606 Shares in AstraZeneca PLC (NASDAQ:AZN) Bought by Fairvoy Private Wealth LLC

Fairvoy Private Wealth LLC bought a new position in AstraZeneca PLC (NASDAQ:AZN) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 4,606 shares of the company’s stock, valued at approximately $302,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of AZN. McClarren Financial Advisors Inc. boosted its holdings in AstraZeneca by 320.8% in the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after purchasing an additional 247 shares during the period. Capital Performance Advisors LLP acquired a new position in shares of AstraZeneca during the third quarter valued at about $28,000. Ashton Thomas Securities LLC bought a new stake in shares of AstraZeneca in the third quarter valued at about $45,000. Albion Financial Group UT grew its position in AstraZeneca by 68.9% during the fourth quarter. Albion Financial Group UT now owns 608 shares of the company’s stock worth $40,000 after buying an additional 248 shares in the last quarter. Finally, Hollencrest Capital Management lifted its position in shares of AstraZeneca by 38.4% in the 3rd quarter. Hollencrest Capital Management now owns 692 shares of the company’s stock worth $54,000 after acquiring an additional 192 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Stock Down 0.5 %

AZN opened at $71.99 on Friday. The firm has a market cap of $223.25 billion, a price-to-earnings ratio of 31.85, a PEG ratio of 1.20 and a beta of 0.46. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. The firm’s 50-day simple moving average is $67.38 and its 200-day simple moving average is $73.69.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Thursday, February 6th. The company reported $1.05 earnings per share for the quarter, missing the consensus estimate of $1.10 by ($0.05). AstraZeneca had a return on equity of 32.55% and a net margin of 13.01%. Equities research analysts anticipate that AstraZeneca PLC will post 4.66 EPS for the current fiscal year.

AstraZeneca Increases Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Monday, March 24th. Stockholders of record on Friday, February 21st will be paid a $1.03 dividend. The ex-dividend date is Friday, February 21st. This is a positive change from AstraZeneca’s previous semi-annual dividend of $0.49. This represents a dividend yield of 2%. AstraZeneca’s dividend payout ratio (DPR) is 43.36%.

Analysts Set New Price Targets

AZN has been the subject of several research reports. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.